Frontiers in Kidney Medicine & Biointelligence

The Renal Research Institute is excited to be back with #Frontiers in Kidney Medicine and Biology, where Dr. Peter Kotanko, Head of Biomedical Evidence Generation and the Renal Research Institute, discusses and shares the latest knowledge and advances in kidney research. In this episode, Dr. Edwina Brown, Consultant Nephrologist and President of the International Society of Peritoneal Dialysis (ISPD) sits down with Dr. Kotanko to talk about her goals as president of the ISPD and her plans to make peritoneal dialysis more accessible to low- and middle- income countries.

Join Dr. Peter Kotanko, MD, FASN, Head of Biomedical Evidence Generation and Renal Research Institute, and John Daugirdas, MD, FACP, FASN, Clinical Professor of Medicine at the University of Illinois School of Medicine at Chicago, as they discuss aspects of dialysis patient prescription.

Join Dr. Peter Kotanko, MD, FASN, Head of Biomedical Evidence Generation and Renal Research Institute, and Peter Stenvinkel, MD, PhD, Professor of Renal Medicine at Karolinska Institutet they discuss the principles of early vascular aging in chronic kidney disease. We will also discuss what we can learn from the animal kingdom in order to identify novel opportunities to slow down the aging process in humans with the burden of lifestyle diseases. We will also discuss the role of and identification of biomarkers of biological age.

Join Drs. Peter Kotanko from the Renal Research Institute and Nicholas Selby from the University of Nottingham for their discussion about hemodialysis, one of the main treatments for kidney failure, but also a treatment that can have adverse consequences. Some of these relate to the 'stress' that dialysis can exert on the cardiovascular system, which in turn affects the delivery of blood to different organs. We will discuss how this happens, what it means for patients, and what can be done to address this.

In this episode, Dr. Peter Kotanko, MD FASN, Research Director from Renal Research Institute is joined by Drs. Valerie Luyckx, MBBCh, MSc, PhD from Children's Hospital in Zurich, Switzerland & Marcello Tonelli, MD, SM, FRCPC from the University of Calgary, as they discuss the intersection between kidney medicine and the United Nations Sustainable Development Goals.

In this episode of Frontiers In Kidney Medicine & Biology, Dr. Peter Kotanko, Research Director at Renal Research Institute (RRI) is joined by Dr. Alhaji Cherif, PhD, Principal Mathematician also from RRI as they discuss the use of mathematical modeling and computations to gain insights into the pandemic in order to provide effective intervention measures and to understand the drivers of the contagion among kidney patients.

In this episode of Frontiers in Kidney Medicine & Biology, Dr. Peter Kotanko, Research Director at Renal Research Institute is joined by Dr. Fokko Pieter Wieringa, PhD, Principal Scientist at IMEC in The Netherlands as they address what pervasive sensing is (including some examples), as well as go into the opportunities and risk of pervasive sensing. If time allows, we will discuss in what direction pervasive sensing may be going.

In this episode, Dr. Peter Kotanko is joined by Dr. Roberto Pecoit-Filho, Senior Research Scientist from the Arbor Research Collaborative for Health, to discuss the differences between anemia in the general population and in patients with kidney disease. We also discuss the current understanding of the mechanisms behind CKD anemia and the perspective of the introduction of new treatment options and an expansion in the understanding of the pathophysiology.

In this session, we join Drs. Peter Kotanko & Bernard Canaud suggest that monthly monitoring of SCI, as part of routine baseline dialysis patient monitoring, will offer a new and cost-effective tool to detect earlier nutritional status deterioration. SCI used as a surrogate marker of active MM would facilitate detection of sarcopenia trends, offering opportunities to implement interventions that might delay, and halt or even reverse such deleterious dynamics. SCI can be easily integrated and used as a first-line tool in complement to visceral proteins (i.e., albumin) to monitor muscle mass changes in clinical routine.